Telesis Bio Raises FY22 Revenue Outlook To 23M - $25M From $22M - $24M Vs. $21.15M Estimate
$DNAY
Medical Specialities
Health Care
Updated 2022 Financial Guidance
The following statements are based on Telesis Bio's current expectations for fiscal 2022. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under "Forward-Looking Statements" below. For the full fiscal year 2022, Telesis Bio provided the following updated financial guidance:
- Revenue is now expected to be between $23 million and $25 million, an increase from previous guidance of $22 million to $24 million.
- Gross margin is expected to be within the 48% to 52% range, consistent with previous guidance.
- Operating expenses including R&D and SG&A are expected to be within the $62 million to $65 million range, consistent with previous guidance.
- Cash on hand is anticipated to be approximately $40 million at the end of 2022.